Key points are not available for this paper at this time.
Design
Editorial
This editorial highlights the ongoing clinical trade-off in heart valve replacement between the limited durability of bioprostheses and the anticoagulation-related bleeding and thromboembolism risks associated with mechanical valves.
Nearly 100 000 heart valves were replaced last year. Almost 20% were in reoperations for prosthetic valve dysfunction. Roughly one half of bioprostheses (which constituted 30% to 40% of all valves implanted) will need to be replaced in 14 years. Despite this reduced durability, some physicians still prefer bioprostheses because the combined problem of thromboembolism and anticoagulant-related bleeding lessens the quality of life with mechanical valves. "Clearly patients with mechanical prosthetic heart valves need a new long-term anticoagulant or a means to self-regulate the dose of warfarin daily." Having said this, the authors do not mention Dupont's new portable device that uses finger-stick blood samples to measure prothrombin time and, analogous to blood glucose self-monitoring in the control of diabetes, may reduce the anticoagulation hazard through better self-control. At one time, bioprosthetics were considered to have a slower, more benign failure mode so that the reoperation could be done at
No takes yet. Share an insight, caveat, or question.
Alan T. Marty (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: